#USA #Monmouth Junction #Creatv MicroTech #CytoDyn #LifeTracDx

Introduction

Creatv Bio, a branch of Creatv MicroTech, Inc., is on the forefront of cancer diagnostics with its innovative LifeTracDx® blood test. This groundbreaking test is set to play a vital role in a significant clinical trial led by CytoDyn Therapeutics Corporation focusing on relapsed or refractory colorectal cancer (CRC).

Collaboration with CytoDyn

CytoDyn has recently received FDA clearance to begin a Phase II clinical trial of leronlimab, a treatment targeting patients whose colorectal cancer is micro-satellite stable. This trial, designated NCT06699835, highlights the growing emphasis on personalized cancer therapy. The collaboration between CytoDyn and Creatv Bio aims to enhance understanding of how patients respond to the leronlimab treatment through the advanced capabilities of the LifeTracDx® test.

What is the LifeTracDx® Test?

The LifeTracDx® test is designed to analyze key biomarkers in patient blood samples. It focuses on two primary components: circulating tumor cells (CTCs) and Cancer Associated Macrophage-Like (CAML) cells. CTCs can shed from tumors into the bloodstream, while CAML cells are specialized immune cells that have engulfed tumor cells. Both types are critical in capturing tumor characteristics and dynamics. By measuring the counts and sizes of CTCs and CAMLs at various time points, the test provides valuable prognostic insights that can predict how patients will respond to treatments.

Importance of Biomarkers

In the context of the CytoDyn trial, understanding the expressions of markers like CCR5 and PD-L1 is crucial. These markers can vary over time, and the LifeTracDx® test allows for dynamic monitoring through non-invasive blood tests, eliminating the need for risky tissue biopsies. This capability can substantially improve the evaluation of treatment effectiveness, paving the way for more tailored cancer therapies that adapt to individual patient responses.

Broader Applications of LifeTracDx®

The implications of the LifeTracDx® test extend beyond this clinical trial. Its applications are diverse, including the early detection of cancer recurrence, assessing the aggressiveness of tumors, and providing crucial information on minimal residual disease. Furthermore, it supports the development of companion diagnostics, which align therapeutic strategies with patient conditions effectively using blood samples rather than traditional tissue samples. This feature not only promotes patient comfort but also facilitates faster decision-making in clinical settings.

The Role of Creatv Bio

Founded with a mission to innovate in cancer diagnosis, Creatv Bio has established itself as a pioneer in using liquid biopsies for predicting treatment responses. The company's research team is credited with the initial discovery of CAML cells in cancer patients' blood, a finding that has opened new avenues in oncology. By partnering with CytoDyn, Creatv is driving forward the fight against cancer with promising technologies aimed at real-time patient monitoring and intervention.

Conclusion

As the LifeTracDx® blood test prepares to assist in the CytoDyn trial, it stands as a testament to the advancements in cancer diagnostics. This collaborative effort showcases the potential to significantly enhance patient care through precision medicine in oncology. With a focus on innovative solutions like LifeTracDx®, the future of cancer treatments is looking increasingly optimistic and tailored to individual needs. For additional insights and information about Creatv Bio, interested parties can visit their official website.